icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
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
PhCG4ndtGM7y1Y0m